OverviewChartNewsTraderScreen

INFLARX N.V. EO 0,12/  NL0012661870  /

Frankfurt
04/10/2024  15:52:01 Chg. -0.0100 Volume Bid21:59:57 Ask21:59:57 High Low
1.3570EUR -0.73% 0
Turnover: 0.0000		 -Bid Size: - -Ask Size: - 1.3940 1.3570
GlobeNewswire 27/08 InflaRx Announces Participation in September Investor Events
GlobeNewswire 08/08 InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 01/08 InflaRx to Report Second Quarter 2024 Results on August 8, 2024
GlobeNewswire 30/07 InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Huma...
GlobeNewswire 24/06 InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel ...
GlobeNewswire 05/06 InflaRx Hosts R&D Event Highlighting the Promise of INF904
GlobeNewswire 21/05 InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Poten...
GlobeNewswire 08/05 InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 30/04 InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2...
GlobeNewswire 24/04 InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
GlobeNewswire 16/04 Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Dir...
GlobeNewswire 22/03 Theratechnologies Appoints Jordan Zwick to its Board of Directors
GlobeNewswire 21/03 InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
GlobeNewswire 19/03 InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
GlobeNewswire 22/02 InflaRx Appoints Jan Medina as Head of Investor Relations
GlobeNewswire 25/01 InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Acc...
GlobeNewswire 04/01 InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with...
GlobeNewswire 06/11/2023 InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
GlobeNewswire 01/11/2023 InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire 11/09/2023 InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C...
GlobeNewswire 30/08/2023 InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill ...
GlobeNewswire 24/03/2022 InflaRx Reports Full Year 2021 Financial and Operating Results
GlobeNewswire 17/03/2022 InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hi...
GlobeNewswire 08/03/2022 InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentat...
GlobeNewswire 28/02/2022 InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa